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The addition of phosphate groups to substrates allows protein kinases to regulate a
myriad of biological processes, and contextual analysis of protein-bound phosphate is
important for understanding how kinases contribute to physiology and disease. Leucine-
rich repeat kinase 2 (LRRK2) is a Ser/Thr kinase linked to familial and sporadic cases of
Parkinson’s disease (PD). Recent work established that multiple Rab GTPases are
physiological substrates of LRRK2, with Rab10 in particular emerging as a human sub-
strate whose site-speciﬁc phosphorylation mirrors hyperactive LRRK2 lesions associated
with PD. However, current assays to quantify Rab10 phosphorylation are expensive,
time-consuming and technically challenging. In back-to-back studies reported in the
Biochemical Journal, Alessi and colleagues teamed up with clinical colleagues and colla-
borators at the Michael J. Fox Foundation (MJFF) for Parkinson’s research to develop,
and validate, a panel of exquisitely sensitive phospho-speciﬁc Rab antibodies. Of particu-
lar interest, the monoclonal antibody-designated MJFF-pRAB10 detects phosphorylated
Rab 10 on Thr73 in a variety of cells, brain extracts, PD-derived samples and human
neutrophils, the latter representing a previously unrecognised biological resource for
LRRK2 signalling analysis. In the future, these antibodies could become universal
resources in the ﬁght to understand and quantify connections between LRRK2 and Rab
proteins, including those associated with clinical PD.
Introduction
Parkinson’s disease (PD) affects ∼1 in 100 people over the age of 60, with the number of sufferers pre-
dicted to increase to >10 million in the world’s most populated nations by 2030 [1]. In the U.K.
alone, over 125 000 people are living with the disease, which is characterised by a range of symptoms,
including neurodegeneration associated with the progressive loss of dopamine-containing neurones
and a broad range of debilitating physical disorders [2]. Various cellular mechanisms have been pro-
posed to contribute to the localised neuronal death that occurs in the substantia nigra of PD brains.
These include protein folding/aggregation defects generating α-synuclein-rich Lewy bodies, abnormal
protein phosphorylation/ubiquitination, aberrant intracellular trafﬁcking and oxidative stress coupled
to mitochondrial dysfunction [3]. None of these potential mechanisms are mutually exclusive, so
piecing together the signalling pathways that might be manipulated pharmacologically for broad PD
patient beneﬁt remains an important goal. Moreover, the unpredictable, and often short-lived, beneﬁts
of classical pharmacological interventions that counteract effects of dopamine depletion in PD would
beneﬁt from stratiﬁed approaches in order to take advantage of druggable lesions in different patient
groups [4].
In the genetic context, ∼20 genes have been directly linked to PD [5], although these currently
account for only ∼5% of all familial cases [6]. An important contributing factor within this population
is the human genomic PARK8 locus on chromosome 12 [7], which encodes the multi-domain
Version of Record published:
5 January 2018
Received: 30 November 2017
Revised: 5 December 2017
Accepted: 6 December 2017
© 2018 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution License 4.0 (CC BY). 185
Biochemical Journal (2018) 475 185–189
https://doi.org/10.1042/BCJ20170870
polypeptide termed LRRK2 (leucine-rich repeat kinase 2). LRRK2 contains an array of structural signalling
motifs alongside protein kinase and GTPase-containing domains [8,9]. Through a combination of poorly
deﬁned enzymatic mechanisms, LRRK2 regulates signal transduction and protein : protein interactions [10]
cytoskeletal dynamics [11], Rab-dependent vesicular trafﬁcking [12] and cellular ciliogenesis [13]. Interestingly,
the majority of evidence put forward to explain how LRRK2 contributes to PD favours abnormal
phosphorylation-dependent signalling properties of mutated enzymes [10]. This includes synergistic contribu-
tions between activating kinase domain mutations, such as the G2019S substitution in the highly conserved
DFG motif found in eukaryotic protein kinases [14] and the tandem Roc/COR (Ras of complex proteins/
C-terminal Of ROC) GTPase-containing domain (e.g. R1441G/C). The potential to treat groups of PD patients
affected by this spectrum of LRKK2-associated mutations [5,15] has made the LRRK2 kinase domain an
important new drug target [16].
Rab GTPase proteins are endogenous LRRK2 substrates
To establish a clear route to the clinic, phosphorylated LRRK2 substrates have been sought as potential biomar-
kers to monitor ‘on-target’ LRRK2 drug engagement and clinical responses. However, until recently, a lack of
validated phosphorylated substrates represented a general roadblock in the ﬁeld. Works from several groups
have established that CNS-active, target-validated small molecule LRRK2 kinase inhibitors have the potential to
interfere with LRRK2-based signalling in PD [16,17]. This potentially includes LRRK2-mediated autophosphor-
ylation on a variety of Ser residues [10,18–21], which have been suggested to represent biomarkers for LRRK2
activity (and might also target it for ubiquitin-mediated degradation) within the emerging LRRK2 signalling
‘module’ [22]. However, and as reiterated in the new studies from Alessi and colleagues [23–25], with the prob-
able exception of pS935 [19] and pS1292 [18], these phosphorylated residues are potentially unreliable as
robust biological readouts to report LRRK2 signalling in cell-based models and patient samples [26].
Recent mass spectrometry-based phosphoproteomics uncovered multiple Rab GTPases as direct physiological
substrates of LRRK2 [12,13,19]. These ﬁndings are interesting for several reasons, not least due to the potential
for phosphoregulation of the Rab proteins, which control multiple aspects of eukaryotic intracellular membrane
trafﬁcking [27]. Moreover, the protein kinase PINK1 (PTEN-induced putative kinase 1; PARK6) and the ubi-
quitin E3 ligase Parkin (PARK2) are also linked to PD signalling upstream of Rab GTPases [28], and the Rab
(Ras-related proteins in brain) GTPase-related protein RAB7L1 (PARK16) functions in a vesicular trafﬁcking
pathway downstream of LRRK2 [29]. Consistently, the Rab proteins were also linked to PD through the analysis
of α-synuclein (PARK1/4) and vesicular trafﬁcking in both yeast and human models [30].
The important discovery — human LRRK2 directly phosphorylates a wide variety of Rab proteins, coupled
with the recent ﬁnding that Rab29 is itself a Golgi LRRK2 activator [31] — opens up a series of new opportun-
ities for researchers. For example, the evaluation of phosphosite preferences reveals that LRRK2-catalyzed phos-
phorylation occurs on a conserved Ser or Thr residue in 14 separate Rab proteins located within the
nucleotide-sensing switch II region of the GTPase domain. These amino acids (Glu-Arg-Phe/Tyr-Arg/His-Ser/
Thr-Hyd, where Hyd=hydrophobic, and Ser/Thr is the site of LRRK2 phosphorylation) conform to the broad
LRRK2 substrate consensus motif previously deﬁned with peptide substrates [32]. The identiﬁcation of such a
wide variety of Rab proteins as physiological LRRK2 substrates means that one obstacle for evaluating LRRK2
signalling output has essentially been overcome, with rapid, quantitative and reproducible Rab phosphorylation
assays becoming a high priority on the research menu.
Towards a comprehensive Rab antibody research toolbox
Now, in a major follow-up to these studies reported in back-to-back papers published in the Biochemical
Journal [23,24], Alessi and co-workers have developed, validated and exploited exquisitely sensitive polyclonal
and monoclonal phospho-speciﬁc Rab antibodies. These include a new monoclonal antibody for rapid detec-
tion of picogramme amounts of Rab10 phosphorylated by LRKK2 at Thr73 (MJFF-pRAB10). Remarkably, the
unique His residue at the −1 position relative to the phosphorylation site in Rab10 appears to have aided cre-
ation of this highly speciﬁc reagent, which avoids cross-reactivity with very similar Rab proteins in this region,
including Rab8A/B and Rab35 [23]. Importantly, Rab10 phosphorylation at Thr73 increases appropriately in a
panel of mouse knockin cells containing hyperactive PD-associated LRRK2 proteins and is prevented by prior
brief exposure to chemical LRRK2 inhibitors [23,24]. Since the detected site of Rab10 phosphorylation is con-
served in mammalian orthologues, this reagent is ideal for analysing Rab10 phosphorylation under a variety of
experimental conditions. For other Rab phospho-speciﬁc antibodies reported (e.g. MJFF-pRAB8), ‘pan-Rab’
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phosphospeciﬁcity was clearly evident, and as conﬁrmed by the authors, the ability of these antibodies to select-
ively immunoprecipitate a variety of phosphorylated Rab proteins, including Rab8A, Rab10 and Rab35, is also
of considerable experimental utility [13,23]. As summarised below, these tools have signiﬁcant potential to
become work-horses in the signalling ﬁeld, because they can be exploited to reveal activation or inhibition of
LRRK2-catalysed phosphorylation in a wide variety of basic and clinical settings.
Initially, the authors focused on raising peptide-based antibodies in a variety of immunogenic hosts, with the
common goal of recognising speciﬁc phosphorylated Rab proteins. Readers are referred to Tables 1 and 2 of
the Lis paper [23] for details of the very broad range of antibodies analysed, and their potential utility in differ-
ent biological scenarios. Depending on the antibody employed, the reagents can be used either as classical
‘primary antibodies’ in immunoblotting-based studies (speciﬁc protocols are described in the Materials and
Methods) or for Rab protein immunoprecipitation from deﬁned lysates. Another useful tool reagent discussed
is a new Rab10 monoclonal antibody, termed MJFF-total Rab10clone-1, which is superior to all previously
described Rab10 antibodies in terms of speciﬁcity and sensitivity [23]. Indeed, an overarching strength of the
experiments reported in these papers is the rigorous analytical work undertaken, including biochemical, tissue-
based and knockout/knockin approaches for antibody evaluation. These experiments have led to the creation of
a benchmarked set of tools from which all researchers in the LRRK2/Rab ﬁeld can beneﬁt, since the consider-
able time invested has resulted in a diverse panel of sensitive and highly selective antibodies.
New LRRK2 : Rab10 analytical opportunities in human
neutrophils?
A biological role for LRRK2 in the immune system has previously been described [33], including marked
increases in proinﬂammatory cytokines in an LRKK2 PD model [34]. However, previous reports did not evalu-
ate LRRK2 mRNA or protein expression in circulating neutrophils. Interestingly, both LRRK2 and Rab10
protein were found to be abundant in puriﬁed neutrophils (and monocytes) at signiﬁcantly higher levels than
in the peripheral blood mononuclear cell population, which was examined side-by-side [24] and in an inde-
pendent study [19]. Excitingly, the highly abundant neutrophil source was puriﬁed and employed for quantiﬁ-
cation of exogenous LRRK2 signalling before and after LRRK2 inhibitor exposure ex vivo, using Rab 10
phosphorylation as an LRRK2 biomarker in neutrophils isolated from a variety of human subjects [24]. It is
logical to speculate that these antibodies might therefore ﬁnd future utility in PD patient-derived neutrophils,
potentially as predictive or responsive biomarkers for reporting LRRK2 activity in appropriately powered
cohorts of subjects, an analysis the authors are careful to point out has not yet taken place [24]. As a priority,
the Rab antibody panel should also be tested for immunoﬂuorescence-based evaluation of Rab phosphoprotein
levels in various fresh or archived cells, tissues and/or patient-derived samples.
Finally, in an experiment to delight biochemical aﬁcionados, Fan et al. demonstrate that to isolate, and quan-
tify, LRRK2 and Rab10 from the protease-rich neutrophil environment, an extract must be prepared in the
presence of an irreversible serine protease inhibitor such as diisopropylﬂuorophosphate (DIFP). Under these
conditions, endogenous Rab 10 Thr35 phosphorylation can also be readily detected in neutrophils by immuno-
blotting [24], with superior signals obtained when compared with those of the (more costly) Phos-tag-based
polyacrylamide electrophoresis procedure [25]. Moreover, the exclusion of DIFP in isolation buffers leads to
rapid LRRK2 proteolysis, yet its inclusion permits stable LRRK2 activity to be quantiﬁed even after 24 h of
sample storage at room temperature. A further impact from this work could therefore be the creation of a for-
malised protocol for the collection and storage of neutrophils from appropriate patients for subsequent LRRK2/
Rab10 analysis. The optimisation of a rapid ELISA-based assay to measure the levels of Rab10 phosphorylation
in samples might be considered a future priority in this context.
Conclusion
Several predicted impacts of these new studies are emphasised. The ﬁrst is the creation of a unique, and very
wide-ranging, consolidated set of pan and speciﬁc Rab antibodies that can be exploited, and perhaps reﬁned,
by pertinent researchers worldwide. They include polyclonal and monoclonal antibody reagents, the latter avail-
able for a prolonged period of time in large amounts, an important consideration for future translational
appraisal. Of equal importance, many of these reagents are, or will soon be, available either commercially or
collaboratively. This published panel [13,16,19,23,24,35] can therefore be employed alongside other tools to
interrogate LRRK2 signalling and Rab protein phosphorylation via conventional immunological procedures.
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However, the utility of these reagents might extend well beyond this rather speciﬁc research area, and their
general availability could inﬂuence current and future generations of research scientists seeking to uncover
LRKK2 and Rab biology associated with health and disease. For example, they could be exploited as basic tools
to probe physiological events associated with human Rab-based phosphorylation in the context of organelle-
based trafﬁcking, including under conditions where endogenous LRRK2 signalling contributes to Rab phos-
phorylation in the absence of LRRK2 mutation (i.e. as part of a normal regulatory cycle). It is notable that the
LRRK2-phosphorylated motif is also very highly conserved in Rab proteins such as Rab10 from yeasts to
worms, ﬂies and vertebrates. In addition, Ras-related Sec4p, the product of the budding yeast SEC4 gene,
whose discovery in 1987 established the Rab ﬁeld [36], shares an identical switch II region with human Rab8A/
B, meaning that phospho-speciﬁc antibodies designed to recognise these human proteins might also be useful
to evaluate whether Sec4p phosphorylation occurs at this site in model organisms from yeast to ﬂies, another
useful LRKK2 model of PD [37]. Secondly, the fruits of these labours now permit the careful analysis of Rab
signalling in a variety of systems speciﬁcally created to model and analyse PD, most notably dynamic Rab10
phosphorylation in the context of PD-associated LRRK2 mutations. It will also be illuminating to extend the
analysis of Rab10 (and perhaps Rab8A/B, whose shared motif for LRRK2 phosphorylation is more challenging
to probe speciﬁcally) phosphorylation in a much larger panel of control and PD brains, focusing on the sub-
stantia nigra and striatum, in addition to the cingulate cortex analysis reported here [23]. Thirdly, and as
explained in some detail by Fan et al. [24], the feasibility, and inherent practicality of analysing LRRK2 and
Rab10 phosphorylation in peripheral (non-CNS) cells, exempliﬁed by the readily isolated neutrophil subpopula-
tion, could lead to changes in PD patient sampling protocols. The ability to quantify pharmacodynamic
changes in Rab protein phosphorylation before, during and after clinical intervention is an obvious outcome in
this context.
These studies represent the latest outputs from a long-term collaboration between basic and clinical LRKK2
scientists, and the MJFF charity created and inspired by Michael J. Fox, whose memorable time-travelling
experiences alongside inventor Christopher Lloyd in the ‘Back to the Future’ ﬁlms inﬂuenced generations of
(somewhat less ambitious) research scientists. Looking forward to the future, we can safely predict that this col-
lection of validated antibodies, many of which bear his name, are likely to have important roles in basic and
clinical settings, including the speciﬁc analysis of Rab phosphorylation in PD patients.
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